April 23rd 2024
At a live virtual event, Leyla Shune, MD, discussed the emergence of talquetamab-tgvs for patients with relapsed/refractory multiple myeloma.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Choosing CAR T-Cell Therapy vs Bispecific Antibodies in Multiple Myeloma
September 8th 2023Selecting and sequencing treatments in relapsed/refractory multiple myeloma involves balancing various factors due to limited historical data, as explained by Ajai Chari, MD, at the 2023 SOHO Annual Meeting.
Read More
Long-Term Depth of Response With Teclistamab Continues in RRMM
August 28th 2023In the first article of a 2-part series, Ajay Nooka, MD, MPH, discussed both the initial and follow-up results of the MajesTEC-1 trial that showed the potency of teclistamab in patients with relapsed/refractory multiple myeloma.
Read More
Participants Debate Which Combination Is Best for High-Risk Multiple Myeloma
August 26th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Joshua Richter, MD, and participants discussed second-line therapy options for a patient with high-risk relapsed multiple myeloma after frontline lenalidomide, bortezomib, and dexamethasone followed by autologous stem cell transplant.
Read More
An Abundance of Approaches Moves Discussion of Sequencing to the Forefront in MM
August 24th 2023During an Oncology Town Hall™ virtual meeting, 4 investigators in multiple myeloma addressed emerging therapies, optimal sequencing, the role of minimal residual disease to inform therapy, and the possibility of storing T cells for use in later CAR T-cell therapy.
Read More
Counseling Patients on Treatment With Selinexor for Multiple Myeloma
August 3rd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Ariel F. Grajales-Cruz, MD, and other physicians discussed how to manage toxicities and counsel patients when using selinexor for relapsed/refractory multiple myeloma.
Read More
Physicians Discuss Options for Second Relapse in Multiple Myeloma
July 26th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Ariel F. Grajales-Cruz, MD, discussed the case of a patient who relapsed after receiving first- and second-line regimens for multiple myeloma. This is the first of 2 articles based on this event.
Read More
Gasparetto Reviews Data for Selinexor Combination Regimen in R/R Multiple Myeloma
July 25th 2023During a Targeted Oncology Case-Based Roundtable event, Cristina Gasparetto, MD, discussed the case of a patient with stage I multiple myeloma and highlighted outcomes of the phase 3 BOSTON trial.
Read More
Daratumumab Shifts Approach in Newly Diagnosed Multiple Myeloma
July 20th 2023In a comparison of 2 live events from the Targeted Oncology Case-Based Roundtable series, we look at how adding daratumumab to therapy for patients with newly diagnosed disease who cannot receive a transplant has shifted the approach to treatment.
Read More
Bispecific Combination Shows Durable Responses in Multiple Myeloma
July 13th 2023In an interview with Targeted Oncology, Yael C. Cohen, MD, senior physician in the Department of Hematology at Tel-Aviv Sourasky Medical Center, discussed the results from RedirecTT-1 she presented at ASCO 2023.
Read More
Physicians Share Perceptions of BCMA-Targeted Therapies for Multiple Myeloma
July 11th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Carol Ann Huff, MD, and other physicians discussed how they expect to use bispecific agents and CAR T-cell therapy in patients with relapsed/refractory multiple myeloma as the field advances.
Read More